Otsuka Signs a Development and Commercialization Agreement with Esperion for Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) in Japan

 Otsuka Signs a Development and Commercialization Agreement with Esperion for Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) in Japan

Otsuka Signs a Development and Commercialization Agreement with Esperion for Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) in Japan

Shots:

  • Esperion to receive $60M up front, $450M as development & commercial milestone and is eligible to receive 15-30% royalties in the sale of products in Japan. Otsuka will get exclusive rights to Nexletol and Nexlizet and will fund Japan-specific development costs associated with the products
  • The collaboration leverages Esperion’s expertise in lipid management and Otsuka’s CV drug development and commercialization expertise in Japan
  • The alliance will advance the commitment of both companies to provide cost-effective, oral, once-daily, non-statin LDL-C lowering therapies for patients with hypercholesterolemia in Japan

Click here ­to­ read full press release/ article | Ref: Business wire  | Image: Otsuka

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post